Significant association of caveolin-1 (CAV1) genotypes with upper urothelial tract cancer

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 4907-4912

  Chang, Wen Shin ^a,b   Lin, Song Shei ^c   Li, Fang Jing ^a,b   Tsai, Chia Wen ^a,b   Li, Long Yuan ^a   Lien, Chi Shun ^b   Liao, Wen Ling ^b   Wu, Hsi Chin ^b   Tsai, Chang Hai ^b   Shih, Tzu Ching ^a,b   Bau, Da Tian ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

CAV1; Genotype; Polymorphism; Upper urothelial track cancer

Indexed keywords

CAVEOLIN 1;

AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TAIWAN; TRANSITIONAL CELL CARCINOMA;

CAV1; GENOTYPE; POLYMORPHISM; UPPER UROTHELIAL TRACK CANCER;

AGED; CASE-CONTROL STUDIES; CAVEOLIN 1; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TAIWAN; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 84891350279     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Carroll P: Urothelial carcinoma: Cancers of bladder, ureter and renal pelvis. In: General Urology, 14th ed. Tanagho EA and McAninch JW (eds.). Philadelphia: Prentice-Hall Int, pp. 353-371, 1995.
2. Yang MH, Chen KK, Yen CC, Wang WS, Chang YH, Huang WJ, Fan FS, Chiou TJ, Liu JH and Chen PM: Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology 59: 681-687, 2002.
3. Mahony JF, Storey BG, Ibanez RC and Stewart JH: Analgesic abuse, renal parenchymal disease and carcinoma of the kidney or ureter. Aust N Z J Med 7: 463-469, 1977.
4. Mellemgaard A, Carstensen B, Norgaard N, Knudsen JB and Olsen JH: Trends in the incidence of cancer of the kidney, pelvis, ureter and bladder in Denmark 1943-88. Scand J Urol Nephrol 27: 327-332, 1993.
5. McLaughlin JK, Silverman DT, Hsing AW, Ross RK, Schoenberg JB, Yu MC, Stemhagen A, Lynch CF, Blot WJ and Fraumeni JF Jr.: Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res 52: 254-257, 1992.
6. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, Kuo TL and Tai TY: Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25: 53-60, 1995.
7. Linet MS, Chow WH, McLaughlin JK, Wacholder S, Yu MC, Schoenberg JB, Lynch C and Fraumeni JF Jr.: Analgesics and cancers of the renal pelvis and ureter. Int J Cancer 62: 15-18, 1995.
8. Liaw KL, Linet MS, McLaughlin JK, Yu MC, Schoenberg JB, Lynch CF, Niwa S and Fraumeni JF Jr.: Possible relation between hypertension and cancers of the renal pelvis and ureter. Int J Cancer 70: 265-268, 1997.
9. Lin HH, Ke HL, Hsiao KH, Tsai CW, Wu WJ, Bau DT and Chang LL: CCND1 1722 polymorphism and potential relevance to upper tract urothelial cancer. Anticancer Res 31: 1043-1047, 2011.
10. Koleske AJ, Baltimore D and Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 92: 1381-1385, 1995.
11. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG and Lisanti MP: Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273: 20448-20455, 1998.
12. Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16: 1391-1397, 1998.
13. Fiucci G, Ravid D, Reich R and Liscovitch M: Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21: 2365-2375, 2002.
14. Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG and Lisanti MP: Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 275: 20717-20725, 2000.
15. Li T, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG, Sparano JA and Lisanti MP: Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 168: 1998-2013, 2006.
16. Greene FL, Page DL and Fleming ID: AJCC Cancer Staging Manual, sixth Edition. New York: Springer-Verlag, 2002.
17. Epstein JI, Amin MB, Reuter VR and Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448, 1998.
18. Wang CH, Lai YL, Chang WS, Wu KH, Lane HY, Chiu CF, Tsai FJ, Lin CC and Bau DT: Significant association of caveolin-1 single nucleotide polymorphisms with childhood leukemia in Taiwan. Cancer Genomics Proteomics 10: 75-79, 2013.
19. Bau DT, Chang CH, Tsai RY, Wang HC, Wang RF, Tsai CW, Yao CH, Chen YS, Shyue SK and Huang CY: Significant association of caveolin-1 genotypes with bladder cancer susceptibility in Taiwan. Chin J Physiol 54: 153-160, 2011.
20. Bau DT, Tsai MH, Tsou YA, Wang CH, Tsai CW, Sun SS, Hua CH, Shyue SK and Tsai RY: The association of caveolin-1 genotypes with oral cancer susceptibility in Taiwan. Ann Surg Oncol 18: 1431-1438, 2011.
21. Hsu CM, Yang MD, Tsai CW, Ho CY, Chang WS, Chang SC, Jeng LB, Tsai Y, Tsai FJ and Bau DT: The contribution of caveolin-1 genotype and phenotype to hepatocellular carcinoma. Anticancer Res 33: 671-677, 2013.
22. Liu LC, Su CH, Wang HC, Tsai CW, Chang WS, Ho CY, Wu CI, Li FJ, Lin CH, Lane HY and Bau DT: Significant association of caveolin-1 (CAV1) genotypes with breast cancer in Taiwan. Anticancer Res 31: 3511-3515, 2011.
23. Tsou YA, Tsai CW, Tsai MH, Chang WS, Li FJ, Liu YF, Chiu CF, Lin CC and Bau DT: Association of caveolin-1 genotypes with nasopharyngeal carcinoma susceptibility in Taiwan. Anticancer Res 31: 3629-3632, 2011.
24. Wu HC, Chang CH, Tsou YA, Tsai CW, Lin CC and Bau DT: Significant association of caveolin-1 (CAV1) genotypes with prostate cancer susceptibility in Taiwan. Anticancer Res 31: 745-749, 2011.
25. Primdahl H, Wikman FP, von der Maase H, Zhou XG, Wolf H and Orntoft TF: Allelic imbalances in human bladder cancer: Genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 94: 216-223, 2002.
26. Hoque MO, Lee CC, Cairns P, Schoenberg M and Sidransky D: Genome-wide genetic characterization of bladder cancer: A comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 63: 2216-2222, 2003.
27. Chang CH, Chang CL, Tsai CW, Wu HC, Chiu CF, Wang RF, Liu CS, Lin CC and Bau DT: Significant association of an XRCC4 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res 29: 1777-1782, 2009.
28. Chang CH, Wang RF, Tsai RY, Wu HC, Wang CH, Tsai CW, Chang CL, Tsou YA, Liu CS and Bau DT: Significant association of XPD codon 312 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res 29: 3903-3907, 2009.
29. Selinski S, Lehmann ML, Blaszkewicz M, Ovsiannikov D, Moormann O, Guballa C, Kress A, Truss MC, Gerullis H, Otto T, Barski D, Niegisch G, Albers P, Frees S, Brenner W, Thuroff JW, Angeli-Greaves M, Seidel T, Roth G, Volkert F, Ebbinghaus R, Prager HM, Lukas C, Bolt HM, Falkenstein M, Zimmermann A, Klein T, Reckwitz T, Roemer HC, Hartel M, Weistenhofer W, Schops W, Rizvi SA, Aslam M, Banfi G, Romics I, Ickstadt K, Hengstler JG and Golka K: Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene. Arch Toxicol 86: 195-203, 2012.
30. Conde MC, Ramirez-Lorca R, Lopez-Jamar JM, Molero E, Ramirez-Armengol JA, Moreno Nogueira JA, Pascual MH, Ruiz A, Martin-Cordova CG, Real LM and Royo JL: Genetic analysis of caveolin-1 and eNOS genes in colorectal cancer. Oncol Rep 16: 353-359, 2006.
31. Yang MD, Tsai RY, Liu CS, Chang CH, Wang HC, Tsou YA, Wang CH, Lin CC, Shyue SK and Bau DT: Association of caveolin-1 polymorphisms with colorectal cancer susceptibility in Taiwan. World J Gastrointest Oncol 2: 326-331, 2010.
32. Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC and Stanford JL: Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 70: 1020-1035, 2010.
33. Sugie S, Tsukino H, Yamauchi T, Mukai S, Fujii M, Shibata N, Kuroda Y and Kamoto T: Functional polymorphism in the CAV1 T29107A gene and its association with prostate cancer risk among Japanese men. Anticancer Res 33: 1023-1027, 2013.
34. Wiggs JL, Kang JH, Yaspan BL, Mirel DB, Laurie C, Crenshaw A, Brodeur W, Gogarten S, Olson LM, Abdrabou W, DelBono E, Loomis S, Haines JL and Pasquale LR: Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma in Caucasians from the USA. Hum Mol Genet 20: 4707-4713, 2011.
35. Thorleifsson G, Walters GB, Hewitt AW, Masson G, Helgason A, DeWan A, Sigurdsson A, Jonasdottir A, Gudjonsson SA, Magnusson KP, Stefansson H, Lam DS, Tam PO, Gudmundsdottir GJ, Southgate L, Burdon KP, Gottfredsdottir MS, Aldred MA, Mitchell P, St. Clair D, Collier DA, Tang N, Sveinsson O, Macgregor S, Martin NG, Cree AJ, Gibson J, Macleod A, Jacob A, Ennis S, Young TL, Chan JC, Karwatowski WS, Hammond CJ, Thordarson K, Zhang M, Wadelius C, Lotery AJ, Trembath RC, Pang CP, Hoh J, Craig JE, Kong A, Mackey DA, Jonasson F, Thorsteinsdottir U and Stefansson K: Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat Genet 42: 906-909, 2010.
36. Chang CH, Wu HC, Ke HL, Lin HH, Shen WC, Sun SS, Tsai CW, Tsai RY and Bau DT: The genetic role of cyclooxygenase 2 in ureter cancer in Taiwan. Adapt Med 3: 99-105, 2011.
37. Hsu LI, Chiu AW, Huan SK, Chen CL, Wang YH, Hsieh FI, Chou WL, Wang LH and Chen CJ: SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. Toxicol Appl Pharmacol 228: 144-155, 2008.
38. Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML and Chen CJ: Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 153: 411-418, 2001.
39. Yang HY, Wang JD, Lo TC and Chen PC: Increased mortality risk for cancers of the kidney and other urinary organs among Chinese herbalists. J Epidemiol 19: 17-23, 2009.
40. Lin HF, Li YH, Wang CH, Chou CL, Kuo DJ and Fang TC: Increased risk of cancer in chronic dialysis patients: A population-based cohort study in Taiwan. Nephrol Dial Transplant 27: 1585-1590, 2011.